BPC-157 Dosage: What the Human Studies Actually Gave

There is no approved BPC-157 dose. No regulator has set one, and no trial has tested one well enough to support it. The published human record is five small studies, three of them with the same first author, and none of them gave BPC-157 by subcutaneous or intramuscular injection, by mouth or on the skin, the four routes that sellers market and that the new HHS compounding policy covers.^[1][2] This page sets out exactly what those studies gave, what the rat studies used, and why neither turns into a dose you can take from a chart.

Is there an approved BPC-157 dose?

No. BPC-157 is not an FDA-approved drug, so there is no label, no approved strength and no approved schedule. When FDA’s reviewers looked at the human data in 2026, they found almost no human pharmacokinetic data. In the enema studies the peptide was not detected, or mostly undetectable, in the blood, and there were no data at all after oral, subcutaneous, nasal or transdermal use.^[1] A dose is normally built on exactly that information: how much reaches the blood, how fast it is cleared, and what amount produces an effect without harm.

The HHS policy announced on October 28, 2026 does not change this. It lets licensed 503A pharmacies compound BPC-157 acetate without federal enforcement action, under conditions, and it names the routes allowed. It names no dose.^[2] We cover what the policy does and does not do in our guide to the HHS peptide compounding policy.

Every dose given to people in a published study

FDA searched PubMed and Embase and found five clinical studies that gave BPC-157 to people.^[1] Two exist only as meeting abstracts from the 2000s, when the Croatian drugmaker Pliva was testing the peptide, code-named PL 14736, for inflammatory bowel disease.^[1][10] The other three are small reports from Florida clinics, published in the same journal between 2021 and 2025, with the same first author.^[3][4][5]

Sources for the table: FDA’s summary of all five studies and its appendix,^[1] and the three published papers.^[3][4][5] The knee paper’s abstract does not state the dose; the 2–4 mg figure is FDA’s reading of the full paper.

“These studies were of short duration, had small sample sizes, evaluated doses that were likely exploratory in nature, and the authors provided limited information on safety data.”^[1]

— FDA briefing document on BPC-157, May 2026

An independent systematic review published in October 2026 reached the same place. It found three human studies with 30 people between them, judged all three to be of poor methodological quality, and rated the overall certainty of the evidence very low.^[6] No dose in the table comes from a published, peer-reviewed trial that compared doses or tested one against placebo.

The routes people use are the ones nobody has studied

Look at the route column again. Enemas, a knee joint, a bladder wall and a vein. The BPC-157 sold to consumers is mostly injected under the skin or swallowed as a capsule, and the HHS policy now covers compounding for subcutaneous, intramuscular, oral and topical forms.^[2] No published human study has used any of those four routes, so there is no human dose on record for them.^[1]

Oral BPC-157 has a particular gap. HHS itself says achieving adequate oral bioavailability of peptides is “inherently difficult and complex,” and it expects a pharmacy compounding an oral form to keep documentation that the specific formulation reaches adequate levels in humans.^[2] In the enema studies, BPC-157 mostly could not be detected in the blood at all.^[1] Whether a capsule delivers anything is the open question we take up in oral BPC-157 capsules.

Registered trials: doses on paper, results not yet

ClinicalTrials.gov lists three credible studies that give BPC-157 by the routes people actually use. None has posted results.

Trial registrations are plans. The 2015 oral study is the only formal safety and pharmacokinetic trial ever registered, and FDA could find neither posted results nor a published paper from it.^[7][1] A fourth listing, for hamstring strains, comes from a sponsor whose TB-500 record opens with the words “This fictional study is an example of a ClinicalTrials.gov-style record,” so it is not evidence of a real trial.^[15] The rotator cuff study has not started.^[8] The gummy study had no comparison group, so even when its results appear they cannot separate the product from the passage of time.^[9]

What the rat studies dosed

Most of what is known about BPC-157 comes from rats, and the rat doses are written per kilogram of body weight. A 2008 tendon study gave 10 micrograms per kilogram (10 µg/kg) into the abdominal cavity once a day.^[11] A 2006 muscle study gave 10 µg/kg, 10 ng/kg or 10 pg/kg by the same route and reported benefit across that range,^[10] which spans a millionfold difference in amount. A 2026 review of the field found that almost all preclinical studies use a single dose, typically 10 µg/kg or 10 ng/kg given into the abdomen or stomach, so the animal work never established a dose-response curve.^[14]

The one formal pharmacokinetic study, in rats and dogs, found a half-life under 30 minutes. It also found that the share of an intramuscular injection reaching the blood was about 14% to 19% in rats and 45% to 51% in dogs.^[12] Two species, the same injection, roughly a threefold difference in exposure. That is the kind of number that has to be measured in people before anyone can say what a human dose should be, and it has not been.

Why a rat dose does not convert to a human one

Online calculators usually multiply a rat µg/kg figure by body weight, or apply a body-surface-area factor. Straight weight scaling ignores the differences in body surface area that the standard method accounts for, and that method divides a rat dose in mg/kg by about 6.2.^[13] Even that method was built for a narrow job. Drug developers use it to estimate a safe first dose for a supervised phase 1 trial, starting from the highest dose that caused no harm in a formal toxicology study, and then they divide by a safety factor of 10.^[13] It does not turn an effective rat dose into an effective human one.

Three more problems apply to BPC-157 in particular:

• The route does not match. Most rat studies gave it into the abdominal cavity or the stomach, routes not used for people.^[14] The same practice guide notes that surface-area conversion is not supported for drugs given by subcutaneous or intramuscular injection, or topically.^[13]
• The safety ceiling is known for one route only. FDA found toxicology limits for intramuscular injection in rats and dogs, but without bioavailability data it said those limits cannot be used to estimate safe levels for oral, subcutaneous or other routes.^[1]
• The effective range is not defined. When the same paper reports benefit at 10 µg/kg and at 10 pg/kg, there is no single animal dose to scale from.^[10]

The 2026 Pharmaceutics review says BPC-157 has “no validated dosing regimen,” and that the regimens used off-label were worked out by informal extrapolation from rodent doses without formal scaling.^[14] The one research group that did a formal surface-area conversion used it to pick doses for its own rat and dog experiments, and no human study has tested the result.^[12]

Why dosage charts and calculators are not evidence

Search for a BPC-157 dosage chart and you will find microgram amounts, schedules, cycle lengths and “loading phases” laid out with some confidence. Check them against the tables above. None of those numbers can be traced to a human study at the route recommended, because no such study has been published. The figures are extrapolations from rats, copied from one seller page to the next, and a calculator built on them inherits the same gap however precise its output looks.

There is also the vial. A research-use-only product carries whatever amount the seller says it does, and the seller usually writes the certificate of analysis too. Our guide to reading a peptide certificate of analysis covers what such a document can and cannot prove. If a prescriber has already written a dose in micrograms, our peptide reconstitution calculator converts it into units on an insulin syringe. It does the arithmetic only. Choosing the dose is the prescriber’s job.

Under the HHS policy, a prescriber sets the dose

The HHS policy covers BPC-157 only when a licensed pharmacy compounds it against a patient-specific prescription, as a single active ingredient, from bulk material with a valid certificate of analysis, in a subcutaneous, intramuscular, oral or topical form.^[2] Compounded drugs are not FDA-approved, and nothing in the policy approves BPC-157.^[2] The dose is whatever the prescriber writes, and the prescriber is writing it without an approved label or a tested regimen behind it.

That makes a few questions worth asking before you start:

1. What is the dose based on? If the answer is a human study, it should be one of the five above, and none of those used the route you are likely to be prescribed.
2. Which pharmacy compounds it, and does it meet the policy’s conditions? A seller that cannot name a licensed pharmacy is selling outside the policy. Our BPC-157 seller comparison lists who sells it.
3. How long, and what monitoring? Every human study above lasted two weeks or less. Ask what the plan is for longer use and what blood work, if any, goes with it.
4. How do I report a problem? The policy requires the pharmacy to report serious adverse events to FDA’s MedWatch and to put the reporting procedure on the patient labeling.^[2]

What is known about harms is just as thin as what is known about doses; we cover it in BPC-157 side effects. For the regulatory history up to the new policy, including FDA’s own recommendation against listing the peptide, see what FDA actually said about BPC-157.

Common questions